The FDA's new due diligence on generic drugs now has one victim: Mallinckrodt, which makes a knockoff version of Johnson & Johnson's ADHD drug Concerta. The Dublin-based drugmaker says the FDA is questioning whether its generic actually measures up to the brand.
There could be a new attention disorder on the block in the future--one that could open up a new patient pool for ADHD drugmakers Eli Lilly, Shire and others. But with pharma critics adept at pointing fingers at companies for "disease-mongering," it's one that could open up a new round of controversy, too.
Johnson & Johnson ($JNJ) continues to cut generics deals over its onetime blockbuster Concerta, as it does what it can to protect sales of the attention-deficit hyperactivity disorder drug.
For the second quarter in a row, Johnson & Johnson posted a downward tick in revenues, hobbled by currency losses. Asset writedowns, legal-settlement set-asides, and acquisition costs dug into earnings.
Shire is taking aim at Johnson & Johnson's ($JNJ) Concerta. The Irish drugmaker is sponsoring two head-to-head trials pitting its ADHD drug Vyvanse against the J&J product as a treatment for adolescents with the disorder.
With sales figures showing that individual psych meds are among Big Pharma's best sellers--think Eli Lilly's ($LLY) Zyprexa, for one--it's no surprise to see the percentage of Americans using drugs
Watson Pharmaceuticals ($WPI) and Johnson & Johnson ($JNJ) have come to an accord on Concerta. J&J will let Watson launch a generic version of the blockbuster ADHD drug next May, as long as
Sales layoffs are on the horizon at Johnson & Johnson as generic versions of the blockbuster ADHD drug Concerta near market. The company has warned the sales force for that drug to prepare for